[{"id":"8551971c-dc39-40b0-a802-ab21b9ec4738","acronym":"","url":"https://clinicaltrials.gov/study/NCT07188740","created_at":"2025-09-27T08:44:07.719Z","updated_at":"2025-09-27T08:44:07.719Z","phase":"Phase 1","brief_title":"Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","source_id_and_acronym":"NCT07188740","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" DNMT3A","pipe":"","alterations":" ","tags":["DNMT3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2025","start_date":" 10/30/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 08/30/2029","study_completion_date":" 08/30/2029","last_update_posted":"2025-09-23"},{"id":"3ed2719e-561e-41cf-943c-89926f1e9bc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05306028","created_at":"2023-12-15T20:17:43.728Z","updated_at":"2025-02-25T13:40:56.951Z","phase":"Phase 2","brief_title":"Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)","source_id_and_acronym":"NCT05306028","lead_sponsor":"Fudan University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"fc853ccb-9f4e-4599-bd19-d2d6e2520e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06044025","created_at":"2023-11-29T19:16:19.395Z","updated_at":"2025-02-25T16:40:12.563Z","phase":"Phase 1","brief_title":"A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy","source_id_and_acronym":"NCT06044025","lead_sponsor":"University of Arkansas","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-06"},{"id":"34985820-886b-4e61-90e7-8b16e17a8048","acronym":"MEMENTO","url":"https://clinicaltrials.gov/study/NCT06687876","created_at":"2025-02-25T19:17:34.383Z","updated_at":"2025-02-25T19:17:34.383Z","phase":"Phase 2","brief_title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","source_id_and_acronym":"NCT06687876 - MEMENTO","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CD163","pipe":"","alterations":" ","tags":["CD163"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"03271227-2174-4789-a946-4de77e418a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04850846","created_at":"2021-04-20T14:55:37.601Z","updated_at":"2024-07-02T16:34:37.692Z","phase":"Phase 2","brief_title":"Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma","source_id_and_acronym":"NCT04850846","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/27/2021","start_date":" 04/27/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"8aa30439-0177-4c65-8336-daf1e74d5099","acronym":"","url":"https://clinicaltrials.gov/study/NCT05023967","created_at":"2021-08-27T13:53:06.078Z","updated_at":"2024-07-02T16:34:59.011Z","phase":"Phase 2","brief_title":"Metformin and Nightly Fasting in Women With Early Breast Cancer","source_id_and_acronym":"NCT05023967","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/04/2023","start_date":" 04/04/2023","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2024-06-04"},{"id":"1c8b1550-7e80-4765-97fb-ec60f41f7c80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04931017","created_at":"2021-06-18T22:52:31.039Z","updated_at":"2024-07-02T16:35:09.374Z","phase":"Phase 2","brief_title":"Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer","source_id_and_acronym":"NCT04931017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1 • IL6 • TNFA","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1 • IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/09/2022","start_date":" 09/09/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-04-16"},{"id":"07dd2c51-fe99-4c3c-9b0a-e4eabf4a89d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01905046","created_at":"2021-01-18T08:34:52.124Z","updated_at":"2024-07-02T16:35:10.772Z","phase":"Phase 3","brief_title":"Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer","source_id_and_acronym":"NCT01905046","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-04-09"},{"id":"d77b6c89-cb48-4369-b0dc-51bba650225a","acronym":"LACC-MET","url":"https://clinicaltrials.gov/study/NCT06353061","created_at":"2024-04-08T18:25:19.565Z","updated_at":"2024-07-02T16:35:11.016Z","phase":"Phase 2","brief_title":"Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT06353061 - LACC-MET","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 04/15/2024","start_date":" 04/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-08"},{"id":"1313c77f-67b2-4152-a25f-375ac9becf7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06215976","created_at":"2024-01-22T19:20:11.478Z","updated_at":"2024-07-02T16:35:22.725Z","phase":"Phase 4","brief_title":"The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer","source_id_and_acronym":"NCT06215976","lead_sponsor":"Cairo University","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-22"},{"id":"a29f772a-28b4-49df-8818-8c35ea1c0c0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05929495","created_at":"2023-07-03T16:10:46.484Z","updated_at":"2024-07-02T16:35:29.842Z","phase":"Phase 2","brief_title":"Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma","source_id_and_acronym":"NCT05929495","lead_sponsor":"University of Milano Bicocca","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-11-09"},{"id":"b7eeda1c-4953-4b53-929a-d79044662260","acronym":"CCTG MA32","url":"https://clinicaltrials.gov/study/NCT01101438","created_at":"2021-01-18T04:21:28.818Z","updated_at":"2024-07-02T16:35:37.413Z","phase":"Phase 3","brief_title":"A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer","source_id_and_acronym":"NCT01101438 - CCTG MA32","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • IGF1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 negative","tags":["HER-2 • PGR • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 3649","initiation":"Initiation: 08/13/2010","start_date":" 08/13/2010","primary_txt":" Primary completion: 09/21/2021","primary_completion_date":" 09/21/2021","study_txt":" Completion: 08/18/2023","study_completion_date":" 08/18/2023","last_update_posted":"2023-09-12"},{"id":"2bab9c7d-960f-48ce-83cf-ed84479f7a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01750567","created_at":"2021-01-18T07:40:45.979Z","updated_at":"2024-07-02T16:35:38.532Z","phase":"Phase 2","brief_title":"A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL","source_id_and_acronym":"NCT01750567","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive • Chr del(11q)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-31"},{"id":"bb23c9d2-5b49-4b1a-9605-371d2ef84038","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122185","created_at":"2021-01-18T09:49:52.228Z","updated_at":"2024-07-02T16:35:38.881Z","phase":"Phase 2","brief_title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02122185","lead_sponsor":"University of Chicago","biomarkers":" CEACAM5 • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Suspended","enrollment":" Enrollment 160","initiation":"Initiation: 02/25/2015","start_date":" 02/25/2015","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2023-08-28"},{"id":"c993e922-769f-409a-a31b-b63aa71e12df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04741945","created_at":"2023-08-01T20:09:13.865Z","updated_at":"2024-07-02T16:35:41.527Z","phase":"Phase 2","brief_title":"Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS","source_id_and_acronym":"NCT04741945","lead_sponsor":"Kirsten Grønbæk","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-01"},{"id":"3dd4e9d1-bbeb-4371-9bec-0586bc49931e","acronym":"METLUNG","url":"https://clinicaltrials.gov/study/NCT05445791","created_at":"2022-07-06T15:54:42.611Z","updated_at":"2024-07-02T16:35:44.678Z","phase":"Phase 3","brief_title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","source_id_and_acronym":"NCT05445791 - METLUNG","lead_sponsor":"Instituto Nacional de Cancerologia de Mexico","biomarkers":" STK11 • AMPK","pipe":" | ","alterations":" EGFR mutation","tags":["STK11 • AMPK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/14/2024","primary_completion_date":" 07/14/2024","study_txt":" Completion: 07/14/2025","study_completion_date":" 07/14/2025","last_update_posted":"2023-06-27"},{"id":"bb9997f0-453a-4083-9fab-d8017d881de5","acronym":"1R01CA172444-01A1","url":"https://clinicaltrials.gov/study/NCT02028221","created_at":"2021-01-18T09:17:16.755Z","updated_at":"2024-07-02T16:35:44.648Z","phase":"Phase 2","brief_title":"Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk","source_id_and_acronym":"NCT02028221 - 1R01CA172444-01A1","lead_sponsor":"University of Arizona","biomarkers":" IGF1 • IGF2 • IGFBP3 • LEP","pipe":"","alterations":" ","tags":["IGF1 • IGF2 • IGFBP3 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2023-06-27"},{"id":"21fdbcab-13c0-42fe-a5bf-250814bf6971","acronym":"","url":"https://clinicaltrials.gov/study/NCT05840068","created_at":"2023-05-03T15:04:36.675Z","updated_at":"2024-07-02T16:35:49.064Z","phase":"Phase 4","brief_title":"IGF Level in Breast Cancer Patients Treated With Metformin","source_id_and_acronym":"NCT05840068","lead_sponsor":"Beni-Suef University","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 07/31/2021","study_completion_date":" 07/31/2021","last_update_posted":"2023-05-03"},{"id":"8adaffcd-4150-46f2-ab7a-bb1fc3fb2178","acronym":"feMMe","url":"https://clinicaltrials.gov/study/NCT01686126","created_at":"2021-01-18T07:18:49.289Z","updated_at":"2024-07-02T16:35:50.456Z","phase":"Phase 2","brief_title":"Improving the Treatment for Women With Early Stage Cancer of the Uterus","source_id_and_acronym":"NCT01686126 - feMMe","lead_sponsor":"Queensland Centre for Gynaecological Cancer","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 10/03/2022","primary_completion_date":" 10/03/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-04-17"},{"id":"405d6ea7-5fc5-409a-a4df-9eea87372fc1","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT04945148","created_at":"2021-06-30T17:54:14.680Z","updated_at":"2024-07-02T16:35:54.530Z","phase":"Phase 2","brief_title":"Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide","source_id_and_acronym":"NCT04945148 - OPTIMUM","lead_sponsor":"Hopital Foch","biomarkers":" FGFR3 • TACC3","pipe":" | ","alterations":" FGFR3 fusion • IDH wild-type","tags":["FGFR3 • TACC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 fusion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 640","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-02-28"},{"id":"7178fa54-7d9b-477c-a5ca-bf696b02b915","acronym":"BREAKFAST","url":"https://clinicaltrials.gov/study/NCT04248998","created_at":"2021-01-18T20:39:01.540Z","updated_at":"2024-07-02T16:35:57.495Z","phase":"Phase 2","brief_title":"Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT04248998 - BREAKFAST","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" HER-2 • PGR • IGF1","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • PGR • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/05/2020","start_date":" 05/05/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-01-18"},{"id":"f96f7635-d369-434a-8c3c-96ed8e311d88","acronym":"","url":"https://clinicaltrials.gov/study/NCT05680662","created_at":"2023-01-11T14:59:16.651Z","updated_at":"2024-07-02T16:35:57.829Z","phase":"Phase 1","brief_title":"The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism","source_id_and_acronym":"NCT05680662","lead_sponsor":"Ministry of Health, Saudi Arabia","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2023-01-11"},{"id":"1f4f5746-c34c-4d2d-b0f5-a6c669df68bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02874430","created_at":"2021-01-18T14:06:47.451Z","updated_at":"2024-07-02T16:35:59.056Z","phase":"Phase 2","brief_title":"Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer","source_id_and_acronym":"NCT02874430","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HER-2 • ER • PGR • CAV1 • SLC16A1","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • CAV1 • SLC16A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/08/2016","start_date":" 06/08/2016","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-12-15"},{"id":"e2ba8f73-021f-4815-bd4f-48ebd4e397b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02278965","created_at":"2021-01-18T10:43:45.075Z","updated_at":"2024-07-02T16:36:05.372Z","phase":"Phase 1","brief_title":"Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer","source_id_and_acronym":"NCT02278965","lead_sponsor":"Katherine D. Crew","biomarkers":" IL6 • IGF1 • IGFBP3 • CRP • IGFBP1 • LEP","pipe":"","alterations":" ","tags":["IL6 • IGF1 • IGFBP3 • CRP • IGFBP1 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 01/22/2015","start_date":" 01/22/2015","primary_txt":" Primary completion: 04/19/2017","primary_completion_date":" 04/19/2017","study_txt":" Completion: 04/19/2017","study_completion_date":" 04/19/2017","last_update_posted":"2022-08-17"}]